WallStSmart

Fennec Pharmaceuticals Inc (FENC)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Fennec Pharmaceuticals Inc generates 6773% more annual revenue ($51.00M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -16.4%. FENC earns a higher WallStSmart Score of 37/100 (F).

FENC

Hold

37

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.3Quality: 4.8
Piotroski: 1/9Altman Z: -2.74

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FENC1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
72.6%10/10

Revenue surging 72.6% year-over-year

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

FENC4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$302.21M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Return on EquityProfitability
-22.2%2/10

ROE of -22.2% — below average capital efficiency

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : FENC

The strongest argument for FENC centers on Revenue Growth. Revenue growth of 72.6% demonstrates continued momentum. PEG of 1.47 suggests the stock is reasonably priced for its growth.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : FENC

The primary concerns for FENC are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

FENC profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

FENC is growing revenue faster at 72.6% — sustainability is the question.

FENC generates stronger free cash flow (2M), providing more financial flexibility.

Bottom Line

FENC scores higher overall (37/100 vs 24/100) and 72.6% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fennec Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States. The company is headquartered in Research Triangle Park, North Carolina.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?